RE:RE:$1M in cash. No PP is needed. 13M free float.I have done my personal DD for WAVE and from a financial position it looks promising. (sorry when some are not interested in all the figures but I think worth to see them). There are some open questions or comments (in bold) perhaps someone has an answer:
Revenue 2019 1’157’274
Cost of Goods 2019 1'108’339
Gross Profit 48’935
Selling & General Expenses 1'375’375
Loss 2019 1'273’805
Working Capital End 2019 998’166
Deficit 5'004’750
Outstanding «shares»
970/k warrants expired in 2019 not excercised
1,750/k options at average excercise price 0,39 remining time 3,6 to 7,8 years
In Q1, 2020 another 275/k options has been granted for a total of 2’025/k
Still a low number of additonal shares comming tot he outstanding shares over the years Key management personnel compensation 264/k
which is very reasonable and shows that the company take care oft he cash Revenue 2019 Q4 272’422
Cost of Goods 2019 Q4 335’067
Gross Loss 2019 Q4 62’645
Loss 2019 Q4 357'596 (28% of 2019)
Bad debt expense was $158,212 for the year ended December 31, 2019. The increase in bad debt expense in the current year was a result of unforeseen delays in collections of payments as a result of COVID-19
Is this really a loss or only received with delays? On January 8, 2020, subsequent to year-end, the Company announced the resignations of both Dr. Theron (Ted) Odlaug as CEO and Pieter de Visser as Chief Financial Officer (“CFO”) and a member of the board of directors, effective December 31, 2019. On January 8, 2020, the Company appointed Mr. Haaris Uddin to the position of CFO.
Has anyone an idea why the two got replaced? Revenue 2020 Q1 393’021
Cost of Goods 2020 Q1 346’133
Gross Loss 2020 Q1 7’112
Loss 2020 Q1 83'630
Working Capital 31.3.2020 757’359
WAV-101 is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma. Currently the brand generates annual revenue of over USD $1 billion. Regulatory filings have been made in the USA, the EU and the UK, and the Company is currently seeking a sales and marketing partner for the EU.
WAV-102 is also an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Currently the brand generates annual revenue of over USD $800 million. Regulatory filings have been made in the USA, the EU and the UK, and the Company is currently seeking a sales and marketing partner for the EU.
On July 30, 2020 Waverley Pharma Announces Grant of Market Authorization for Pemetrexed and Bortezomib in Multiple European Countries (Belgium, the Czech Republic, Germany, Ireland, the Netherlands, and the United Kingdom)
Are the two products under WAV-101 or WAV-102 or both? Annual revenu is a nice figure but - What will be the new revenue for WAVE
- What marketshare can they grab